Demographics

Number of patients

N = 197

Male

N = 95 (48.2%)

Female

N = 102 (51.8%)

Age in years

Mean: 72.7; Range: 41 - 97

Follow up in months

Mean: 40; Median: 28; Range: 2 - 230

Overall Survival in months

Median: 28; Mean: 76.8

Stage

I (combining IA with IB)

N = 117 (59.4%)

II or III

N = 18 (9.1%)

IV (metastatic lesions)

N = 42 (21.3%)

Histology

Adenocarcinoma

N = 79 (40.1%)

Squamous cell carcinoma

N = 38 (19.3%)

Lung carcinoma (multiple types)

N = 38 (19.3%)

Non-lung carcinoma (multiple types)

N = 42 (21.3%)

Laterality

Right

N = 113 (57.4%)

Left

N = 84 (42.6%)

Prescription

50 Gy in 5 fractions

N = 69 (35%)

48 Gy in 4 fractions

N = 128 (65%)

Lung dosimetry

Left Lung Dose (2 Gy Equivalent)

Mean: (5.3 ± 6.1) Gy; Range: [0.17 - 33.9] Gy

Median: (0.6 ± 1.1) Gy; Range: [0.03 - 8.8] Gy

Right Lung Dose (2 Gy Equivalent)

Mean: (6.0 ± 5.9) Gy; Range: [0.2 - 25.6] Gy

Median: (0.8 ± 1.23) Gy; Range: [0.06 - 8.2] Gy

Left Lung V%_20 (2 Gy Equivalent)

Mean: (0.06 ± 0.08); Range: (0 - 0.37)

Right Lung V%_20 (2 Gy Equivalent)

Mean: (0.07 ± 0.08); Range: (0 - 0.34)

Both Lungs V%_20 (2 Gy Equivalent)

Mean: (0.066 ± 0.036); Range: (0.01 - 0.18)

Targets

PTV Volume (cm³)

Mean: (52.1 ± 62.64); Range: [7.2, 427.7]

PTV Effective Radius (cm)

Mean: (2.3 ± 2.5); Range: [1.2, 4.7]